These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 22870802)

  • 1. First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor.
    Im DS
    Arch Pharm Res; 2012 Jun; 35(6):945-8. PubMed ID: 22870802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipids and eicosanoids in fibrosis: emerging targets for therapy.
    Castelino FV
    Curr Opin Rheumatol; 2012 Nov; 24(6):649-55. PubMed ID: 22810365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Druggable Lysophospholipid Signaling Pathways.
    Yanagida K; Valentine WJ
    Adv Exp Med Biol; 2020; 1274():137-176. PubMed ID: 32894510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of modulators for lysophosphatidic acid receptors: A comprehensive review.
    Liu W; Hopkins AM; Hou J
    Bioorg Chem; 2021 Dec; 117():105386. PubMed ID: 34695732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.
    Volkmann ER; Denton CP; Kolb M; Wijsenbeek-Lourens MS; Emson C; Hudson K; Amatucci AJ; Distler O; Allanore Y; Khanna D
    Eur Respir Rev; 2024 Apr; 33(172):. PubMed ID: 39009409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidic acid-1-receptor targeting agents for fibrosis.
    Rancoule C; Pradère JP; Gonzalez J; Klein J; Valet P; Bascands JL; Schanstra JP; Saulnier-Blache JS
    Expert Opin Investig Drugs; 2011 May; 20(5):657-67. PubMed ID: 21434838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox.
    Llona-Minguez S; Ghassemian A; Helleday T
    Prog Lipid Res; 2015 Apr; 58():51-75. PubMed ID: 25704399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future direction in the management of scleroderma.
    Brady SM; Shapiro L; Mousa SA
    Arch Dermatol Res; 2016 Sep; 308(7):461-71. PubMed ID: 27139430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis.
    Tager AM
    Am J Respir Cell Mol Biol; 2012 Nov; 47(5):563-5. PubMed ID: 23125419
    [No Abstract]   [Full Text] [Related]  

  • 10. Emerging drugs for idiopathic pulmonary fibrosis.
    Thannickal VJ; Flaherty KR; Hyzy RC; Lynch JP
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):707-27. PubMed ID: 16262559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Physiological role of lysophosphatidic acid and its relevancephysiological role of lysophosphatidic acid and its relevance to diseases].
    Shimizu Y; Tokumura A
    Seikagaku; 2011 Jun; 83(6):506-17. PubMed ID: 21800681
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent advances in pulmonary fibrosis: implications for scleroderma.
    Homer RJ; Herzog EL
    Curr Opin Rheumatol; 2010 Nov; 22(6):683-9. PubMed ID: 20693906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
    Swaney JS; Chapman C; Correa LD; Stebbins KJ; Broadhead AR; Bain G; Santini AM; Darlington J; King CD; Baccei CS; Lee C; Parr TA; Roppe JR; Seiders TJ; Ziff J; Prasit P; Hutchinson JH; Evans JF; Lorrain DS
    J Pharmacol Exp Ther; 2011 Mar; 336(3):693-700. PubMed ID: 21159750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two new drugs for idiopathic pulmonary fibrosis.
    Med Lett Drugs Ther; 2014; 56(1457):123-4. PubMed ID: 25461229
    [No Abstract]   [Full Text] [Related]  

  • 15. Innovative antifibrotic therapies in systemic sclerosis.
    Beyer C; Distler O; Distler JH
    Curr Opin Rheumatol; 2012 May; 24(3):274-80. PubMed ID: 22450392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
    Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
    Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophospholipids--receptor revelations.
    Hla T; Lee MJ; Ancellin N; Paik JH; Kluk MJ
    Science; 2001 Nov; 294(5548):1875-8. PubMed ID: 11729304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction.
    Pechkovsky DV; Prasse A; Kollert F; Engel KM; Dentler J; Luttmann W; Friedrich K; Müller-Quernheim J; Zissel G
    Clin Immunol; 2010 Oct; 137(1):89-101. PubMed ID: 20674506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactive lysophospholipids and their G protein-coupled receptors.
    Moolenaar WH
    Exp Cell Res; 1999 Nov; 253(1):230-8. PubMed ID: 10579925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of lysophosphatidic acid in cancer.
    Mills GB; Moolenaar WH
    Nat Rev Cancer; 2003 Aug; 3(8):582-91. PubMed ID: 12894246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.